Astria Therapeutics (ATXS) Profit After Tax: 2017-2018
Historic Profit After Tax for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$6.1 million.
- Astria Therapeutics' Profit After Tax fell 10.24% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$25.9 million, marking a year-over-year increase of 5.46%. This contributed to the annual value of -$25.9 million for FY2018, which is 5.46% up from last year.
- Per Astria Therapeutics' latest filing, its Profit After Tax stood at -$6.1 million for Q4 2018, which was down 6.71% from -$5.7 million recorded in Q3 2018.
- In the past 5 years, Astria Therapeutics' Profit After Tax ranged from a high of -$5.5 million in Q4 2017 and a low of -$7.9 million during Q1 2017.
- Over the past 2 years, Astria Therapeutics' median Profit After Tax value was -$6.7 million (recorded in 2017), while the average stood at -$6.7 million.
- Within the past 5 years, the most significant YoY rise in Astria Therapeutics' Profit After Tax was 19.07% (2018), while the steepest drop was 10.24% (2018).
- Over the past 2 years, Astria Therapeutics' Profit After Tax (Quarterly) stood at -$5.5 million in 2017, then fell by 10.24% to -$6.1 million in 2018.
- Its last three reported values are -$6.1 million in Q4 2018, -$5.7 million for Q3 2018, and -$6.5 million during Q2 2018.